BioTechnique, LLC (“BioTechnique”) announced today the launch of the second phase of manufacturing in partnership with a major, international not-for-profit organization. Under this partnership, BioTechnique will manufacture a commercially-available vaccine product in a new, shelf-stable dosage form. In the first phase of manufacturing, BioTechnique produced the same vaccine product in late 2015. The vaccine met all analytical and release testing specifications and entered the clinic in early 2016.
“We are very pleased to support a major non-profit trust in bringing their novel dosage form to market,” said John Clapham, BioTechnique CEO. “With the continuation of this live attenuated virus manufacturing partnership, we have broadened our ability meet demand from our customers who need a reliable contract manufacturing partner.”
“The successful completion of our first project marked our official transition into an operational CMO. This feat could not have been accomplished without a team effort from the BioTechnique organization. Our previous accomplishments indicate we are well-situated to continue this momentum into phase II of this partnership,” stated Raphi Hanessian, General Manager, BioTechnique.
– Reposted from Business Wire